The Zhitong Finance App learned that Changjiang Life Technology (00775) rose 20% in the afternoon. As of press release, it had risen 9.68% to HK$0.34, with a turnover of HK$5.9977 million.
According to the news, Changjiang Life Science announced in the afternoon that it will show how its artificial intelligence driven (AI) platform can be applied to design cancer vaccines at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) to be held in San Diego, USA, with partner XtalPi (XtalPi). The two sides discovered that the AI model developed in the research collaboration can significantly improve the design of novel antigen peptide vaccines, and is superior to the most advanced prediction algorithms in predicting the presentation of MHC-I and MHC-II antigens.
Furthermore, at the AACR 2024 conference, the company plans to present new data from two sets of preclinical research studies on rat sarcoma virus oncogene (KRAS) and cell-mediated death-ligand 1 (PD-L1), respectively. The company believes that the preclinical efficacy results of research cancer vaccines targeting KRAS and PD-L1 proteins are encouraging, and the company hopes to advance these vaccines and other vaccines to the clinical research stage in the future.